Anemia of Chronic Kidney Disease Clinical Trial
Official title:
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of Subcutaneous CKD-11101 Versus Darbepoetin Alfa in Patients Who Had Renal Anemia Not on Dialysis
The aim of this study was to compare and evaluate efficacy and safety of subcutaneous CKD-11101 versus Darbepoetin alfa in patients who have renal anemia not on dialysis.
This was designed as randomized, double-blind, multi-center, Phase 3 clinical study to
evaluate the efficacy and safety of subcutaneous CKD-11101 versus Darbepoetin Alfa in
patients who had stage 3, stage 4, and stage 5 chronic renal failure not on hemodialysis or
peritoneal dialysis.
The selection criteria will be evaluated in patients who are receiving anemia correction
among patients with 19 years of age or older and who had anemia in chronic renal failure of
stage 3 or above.
Subjects who are identified to meet all inclusion criteria will be randomized to test group
and control group at 1:1 ratio and go through 24-week correction period and efficacy
evaluation period. During correction period and efficacy evaluation period, subjects will
visit the clinical study center every 2 weeks to receive processes designated for each visit
and be administered investigational product from the investigator in charge of drug
administration.
In the safety evaluation period, all subjects will be administered test drug for 28weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03325621 -
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02198495 -
Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients
|
Phase 4 | |
| Suspended |
NCT03193073 -
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
|
N/A | |
| Completed |
NCT02581124 -
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
|
Phase 1 | |
| Completed |
NCT02268994 -
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
|
Phase 3 | |
| Completed |
NCT04543812 -
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
|
Phase 3 | |
| Recruiting |
NCT05900635 -
Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients
|
Phase 4 | |
| Completed |
NCT04667533 -
Desidustat in the Treatment of Chemotherapy Induced Anemia
|
Phase 1 | |
| Completed |
NCT03731741 -
Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?
|
Phase 2 | |
| Completed |
NCT02787824 -
Periodic Versus Continuous IV Iron Supplementation in HD Patients
|
Phase 4 | |
| Completed |
NCT01971164 -
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
|
Phase 1 | |
| Recruiting |
NCT01532349 -
Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT05698420 -
Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
|
||
| Completed |
NCT03427801 -
Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
|
||
| Recruiting |
NCT03521713 -
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
|
Phase 3 | |
| Active, not recruiting |
NCT02754167 -
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT02805244 -
Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis
|
Phase 1 | |
| Completed |
NCT03428594 -
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
|
Phase 3 | |
| Not yet recruiting |
NCT06352138 -
Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients
|
Phase 3 | |
| Suspended |
NCT05082571 -
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease
|
Phase 3 |